Class summary at a glance.

Every drug in the Folate Analog Metabolic Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $93.3Mcombined across class
Total Rx claims: 3.7M1.0M unique beneficiaries
Generic mfrs (active): 28across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Methotrexate

Brand: JYLAMVO · 3.6M Part D claims (CY24) · 1.0M beneficiaries · First FDA approval: 1990-11-01

14 generic mfrs 770 plans require PA Active FDA shortage

Low NADAC$0.158

→

Avg plan cost$134.29

Part D spend $88.7M 847× spread, current vs floor

Class share

95%

of class CY24 spend

View profile →

Pemetrexed Disodium

Brand: Alimta · 3K Part D claims (CY24) · 746 beneficiaries · First FDA approval: 2004-02-04

13 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $4.5M

Class share

of class CY24 spend

View profile →

Pemetrexed

Brand: AXTLE · 61 Part D claims (CY24) · 11 beneficiaries · First FDA approval: 2022-02-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $62837

Class share

of class CY24 spend

View profile →

Pemetrexed Dipotassium

— Part D claims (CY24) · First FDA approval: 2025-01-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Pralatrexate

Brand: Folotyn · — Part D claims (CY24) · First FDA approval: 2009-09-24

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.